View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 18, 2020updated 04 Sep 2020 6:31am

Chinese official says Fujifilm’s Favipiravir could treat Covid-19

China’s Science and Technology Ministry official Zhang Xinmin has said that Japan-based Fujifilm’s anti-flu drug Favipiravir helped Covid-19 patients recover.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

China’s Science and Technology Ministry official Zhang Xinmin has said that Japan-based Fujifilm’s anti-flu drug Favipiravir helped Covid-19 patients recover.

Developed by Fujifilm Toyama Chemical, and also referred to as Avigan, Favipiravir gained approval in Japan in 2014.

In 2016, Japan provided Favipiravir as emergency aid for the Ebola virus outbreak in Guinea, noted Reuters.

The drug received Chinese approval for manufacturing by Zhejiang Hisun Pharmaceutical to treat adults with new or recurring influenza, according to a filing by the company last month.

Last month, Chinese media reported that the drug received approval as an investigational therapy for Covid-19 coronavirus infection.

In Shenzhen city in China, a clinical trial involving 80 participants demonstrated better chest improvement in those treated with Favipiravir, noted Zhang.

Also, patients treated with the drug tested negative for the genomic trace of the virus in lesser time, compared to those not administered with the drug.

The drug was able to shorten the recovery time from 11 days to four days for mild and regular cases.

Another trial in Wuhan showed that the drug shortened fever duration from an average of 4.2 days to 2.5 days.

Zhang said that Favipiravir has been effective, without any obvious side-effects, in helping coronavirus patients recover.

Fujifilm had no comment on the Chinese government’s announcement. The company produces Avigan only when the Japanese government provides orders and has no sales target, said a Fujifilm spokeswoman.

The company’s shares increased by 15% on Wednesday morning after the announcement.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology